Korro Bio, Inc. Proceeds from Stock Options Exercised
Korro Bio, Inc. (KRRO) reported Proceeds from Stock Options Exercised of $17.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-06
- Korro Bio, Inc. proceeds from stock options exercised for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Korro Bio, Inc. proceeds from stock options exercised for the quarter ending 2026-03-31 was $17.00K, a 90.12% decline year-over-year.
- Korro Bio, Inc. proceeds from stock options exercised for the quarter ending 2025-12-31 was $380.00K, a 59.18% decline year-over-year.
- Korro Bio, Inc. proceeds from stock options exercised for the quarter ending 2025-09-30 was $128.00K, a 82.42% decline year-over-year.
- Korro Bio, Inc. proceeds from stock options exercised for fiscal 2025 was $685.00K, a 65.23% decline from fiscal 2024.
- Korro Bio, Inc. proceeds from stock options exercised for fiscal 2024 was $1.97M, a 180.63% increase from fiscal 2023.
- Korro Bio, Inc. proceeds from stock options exercised for fiscal 2023 was $702.00K, a 1032.26% increase from fiscal 2022.
- Korro Bio, Inc. proceeds from stock options exercised for fiscal 2022 was $62.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $17.00K 10-Q · filed 2026-08-06 | $397.00K derived: sum of 3 quarters · filed 2026-08-06 | $525.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $17.00K 10-Q · filed 2026-05-07 | $397.00K derived: sum of 2 quarters · filed 2026-05-07 | $525.00K derived: sum of 3 quarters · filed 2026-05-07 | $530.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $508.00K derived: sum of 2 quarters · filed 2026-03-12 | $513.00K derived: sum of 3 quarters · filed 2026-08-06 | $685.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $128.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $133.00K derived: sum of 2 quarters · filed 2026-08-06 | $305.00K 10-Q · filed 2025-11-12 | $1.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $177.00K 10-Q · filed 2026-08-06 | $1.11M derived: sum of 3 quarters · filed 2026-08-06 | $1.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $172.00K 10-Q · filed 2026-05-07 | $1.10M derived: sum of 2 quarters · filed 2026-05-07 | $1.83M derived: sum of 3 quarters · filed 2026-05-07 | $2.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $931.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.66M derived: sum of 2 quarters · filed 2026-03-12 | $1.83M derived: sum of 3 quarters · filed 2026-03-12 | $1.97M 10-K · filed 2026-03-12 |
| 2024-09-30 | $728.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $900.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.04M 10-Q · filed 2025-11-12 | $1.39M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $172.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $311.00K 10-Q · filed 2025-08-12 | $664.00K derived: sum of 3 quarters · filed 2025-08-12 | $880.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $139.00K 10-Q · filed 2025-05-07 | $492.00K derived: sum of 2 quarters · filed 2025-05-07 | $708.00K derived: sum of 3 quarters · filed 2025-05-07 | $790.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $353.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $569.00K derived: sum of 2 quarters · filed 2025-03-18 | $651.00K derived: sum of 3 quarters · filed 2025-03-18 | $702.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $216.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $298.00K derived: sum of 2 quarters · filed 2024-11-12 | $349.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $82.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $133.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $51.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $62.00K 10-K · filed 2024-03-26 | |||
| 2021-09-30 | $288.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $616.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.19M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $328.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $900.00K 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $572.00K 10-Q · filed 2021-05-13 | |||
| 2020-09-30 | $462.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $853.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.16M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $391.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $700.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $309.00K 10-Q · filed 2021-05-13 | |||
| 2019-09-30 | $325.00K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |